bucindolol

04/01/2004 - "The only exception is the Beta Blocker Evaluation of Survival Trial (BEST) that studied the efficacy of Bucindolol in heart failure. "
09/01/1990 - "Significant improvement was seen in the bucindolol group using invasive and noninvasive tests; treadmill time increased from 445 to 530 seconds (p = 0.04), Minnesota Living With Heart Failure Questionnaire score improved from 61 to 40 (p = 0.0001), cardiac output increased from 4.0 to 4.7 (p = 0.02), and systemic vascular resistance decreased from 1,888 to 1,481 (p = 0.04). "
03/01/2001 - "Bucindolol, an investigational beta-blocker, showed only mild improvement in survival in patients with heart failure. "
04/01/1994 - "In heart failure from systolic dysfunction, beta-blockade with bucindolol produces a dose-related improvement in and prevents deterioration of left ventricular function."
03/01/1981 - "The combination of myocardial stimulation and vasodilatation which contributed to the positive results in this acute model of pump failure suggests a possible role for bucindolol in the clinical management of congestive heart failure. "

01/01/2021 - "Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype."
12/01/2017 - "Through this, we will understand how bucindolol may help patients with atrial fibrillation and heart failure with reduced ejection fraction (AF-HFrEF), which carries poor prognosis. "
12/01/2017 - "Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure."
04/01/2017 - "Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients."
06/01/2015 - "Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure."

05/01/2004 - "We performed a retrospective study using a large register from the Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT). "
12/01/2003 - "3166 consecutive patients screened for entry in the Bucindolol Evaluation in Acute Myocardial Infarction Trial with definite acute myocardial infarction and echocardiographic assessment of left ventricular systolic function were included between 1998 and 1999 in this prospective observational study. "
08/01/2002 - "The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT)."
08/01/2002 - "The aim of this study was to evaluate the efficacy of adding the beta-blocker bucindolol to standard therapy shortly after a myocardial infarction in a high-risk population with reduced left ventricular function. "
08/01/2002 - "Due to early closure it is unknown whether bucindolol changes mortality in high-risk post myocardial infarct patients when added to best medical therapy. "

11/01/1987 - "Efficacy of bucindolol in systemic hypertension."
04/01/1985 - "Short- and long-term studies of bucindolol in mild to moderate hypertension: efficacy, safety, and exercise responses."
05/01/2004 - "Importance of a history of hypertension for the prognosis after acute myocardial infarction--for the Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT) study group."
10/01/1985 - "Single doses of bucindolol 50, 100 and 200 mg were compared to placebo and single doses of oxprenolol 40, 80 and 160 mg in seven patients with mild hypertension, in a double-blind randomized study. "
11/01/1985 - "The pharmacokinetics of bucindolol and its major metabolite, 5-hydroxybucindolol, have been studied in eight patients with mild/moderate hypertension. "

05/01/1991 - "Bucindolol, a new beta-blocker, showed favorable effects in a short-term (3 month) trial in idiopathic dilated cardiomyopathy. "
12/01/1991 - "We investigated the effects of bucindolol, a nonselective, non-ISA beta-blocker with mild-vasodilatory properties, in patients with congestive heart failure from ischemic dilated cardiomyopathy (ISCDC, n = 27) and compared the results with those in subjects with heart failure from idiopathic dilated cardiomyopathy (IDC, n = 22). "
12/01/1991 - "Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy."
05/01/1991 - "Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy."
03/01/1990 - "In this study, we evaluated the effects of long-term bucindolol therapy in the treatment of heart failure from idiopathic dilated cardiomyopathy. "